This year marks my third consecutive year attending this amazing conference of 40,000+ attendees. And every year it has proven to be transformative in terms of science and clinical advances for oncology professionals from around the world there to discuss state-of-the-art treatment modalities, new therapies, and ongoing developments in the field. Having focused much of […]Read Full Article
Welcome to the Blue Fin Group Information Library. Our consultants regularly publish white papers, case studies and articles, lead workshops, deliver speaking engagements, and share opinions on topics of interest to decision makers in the healthcare industry.
You don’t become an industry leader without having alot to say—click on the video vignettes below to hear our expert’s perspectives on a range of topics.
Blue Fin Group is often sought out as an expert commentator by industry publications — featuring our latest thinking and timely insights on the issues that matter most to the healthcare industry.
Blue Fin Group keeps a lens trained on many facets of the healthcare industry, and our white papers focus on singular topics that are relevant and timely. Known for our out-of-the-box thinking, these insights provide a deeper dive or different viewpoint from what others in the industry provide.
Case studies that show the transformation from challenge to solution. Each one details the existing situation, Blue Fin Group’s unique approach, the solution deployed, and the results achieved on behalf of the client. At Blue Fin Group, we deliver Deep Knowledge. Powerful Results.
Deep knowledge, unique insights and powerful perspectives focused on the healthcare industry, provided by Blue Fin Group associates.
Managing Partner John Cervione was interviewed at the recent Asembia Summit regarding his insights into Amazon entering the healthcare arena. In this clip, he reveals what one key element is missing for success.
Only a small percentage of the rare diseases that have been identified have approved therapies available to treat them. However, more and more orphan /rare disease (ORD) drugs are being developed and approved for use in the U.S. market. In fact, according to the FDA’s Orphan Drug Designations and Approvals database, there have been 668 […]Read Full Article
The theme of this year’s Rare Disease Day is research. Using the hashtag #ShowYourRare, brave souls from all over the world are sharing their stories of the as many as 7,000 rare diseases that 300 million people globally and 30 million in the US have to learn to live with every day unless we can […]Read Full Article
Principal Consultant Jason Bogroff asks us to think about data use differently; not as discrete reports, but instead as an ongoing process of drill-down, questioning and analysis to reveal untapped value from our data assets.Read Full Article
PRx is huge. Most of the money is coming from drugs. Everyone is talking about the science and the challenges with getting PRx to work in hospitals. Yet no one is talking about commercial strategies, and it’s time to do so now.Read Full Article
Blue Fin Group wishes a very Happy Holiday season to all! Looking forward to 2018 to continue doing what we do best…Read Full Article
Phyllis Kidder, PharmD, Principal Consultant, attended the recent PCMA Annual Meeting in Scottsdale and came away with two over-arching themes: First, innovation and disruption in healthcare is here and will accelerate over the next few years. As Mostafa Kamal said “if you are not the disruptor, you are going to be disrupted”. Innovation encompasses technology, which […]Read Full Article